Agreements with Celonic Group of Switzerland and Germany’s Wacker can be terminated however current production offers with Rentschler Biopharma and Novartis would stay unchanged, CureVac stated in an announcement.
CureVac fell far behind rivals BioNTech, a associate of Pfizer, and Moderna, in making an attempt to develop an mRNA-primarily based COVID-19 vaccine.
“The continuous increase in mRNA manufacturing capacity together with the progress of large-scale vaccination efforts have strongly changed the demand for our first-generation COVID-19 vaccine, CVnCoV, over the last months,” stated CureVac Chief Operating Officer Malte Greune.
CureVac in June and July printed disappointing trial knowledge on its preliminary vaccine candidate, and European regulatory approval is but excellent.
It can be working with GlaxoSmithKline on a subsequent era of COVID-19 vaccines.
#Note-Author Name –